Time for a change: considering the rights of study participants to ownership of their personal research-grade genomic data
- 1 December 2018
- journal article
- research article
- Published by IOP Publishing in Convergent Science Physical Oncology
- Vol. 4 (4), 046001
- https://doi.org/10.1088/2057-1739/aaf822
Abstract
Determining the ownership of a patient's personal genomic data is important because it impacts how data is governed and shared, which has both clinical and research implications for precision oncology. The 21st Century Cures Act enacted in December 2016 defined the ownership of clinical genomic data, but the governance of research-grade genomic data remains a hotly contested topic. The many stakeholders often have competing perspectives about ownership of raw and processed genomic data derived in research settings and how to weigh risks versus benefits of sharing this data with study participants. A growing number of research studies, policy recommendations, and ethics reviews have not been enough to influence changes in practice. Most genomic research is conducted in academia, which is guided by Institutional Review Board-approved protocols to protect study participants. The current standard is to limit the return of research-grade data to study participants, and give data ownership solely to the researchers or the research institution, since this data is not vetted for clinical purposes and is meant for research use only. However, these practices conflict not only with recommendations from peer-reviewed literature on best practices for addressing research study participants' needs but might indeed run counter to legal and ethical guidelines about data ownership. For example, patient-participants faced with poorly understood or incurable diseases such as certain cancers want, and could potentially benefit from, having access to their personal genomic data in this rapidly evolving field. This commentary highlights the gap between the status quo as approved by the IRB and the literature suggesting that study participants should be given access to their personal genomic data. There is an opportunity to facilitate a more effective and ethical way to collect genomic data for research use across institutions.Keywords
This publication has 30 references indexed in Scilit:
- Genes, cells, and biobanks: Yes, there’s still a consent problemPLoS Biology, 2017
- Data Sharing and the Idea of OwnershipThe New Bioethics, 2017
- Past, Present, and Future of Informed Consent in Pain and Genomics Research: Challenges Facing Global Medical CommunityPain Practice, 2016
- Institutional review board perspectives on obligations to disclose genetic incidental findings to research participantsGenetics in Medicine, 2016
- A comparison of institutional review board professionals’ and patients’ views on consent for research on medical practicesClinical Trials, 2016
- Challenges to Implementation of Global Translational Collaboration PlatformsMOJ Proteomics & Bioinformatics, 2015
- Use of altered informed consent in pragmatic clinical researchClinical Trials, 2015
- Informed consent for human genetic and genomic studies: a systematic reviewClinical Genetics, 2014
- Security and privacy requirements for a multi-institutional cancer research data grid: an interview-based studyBMC Medical Informatics and Decision Making, 2009
- From genetic privacy to open consentNature Reviews Genetics, 2008